Tag: Inflammatory bowel disease

According to prescribing information, the treatment plan for Skyrizi in adults with Crohn's disease is divided into two distinct phases: an initial intravenous (IV) induction period followed by subcutaneous (SC) maintenance injections. For those wondering **how often should I skyrizi for Crohn's**, the frequency starts with three initial IV doses and then transitions to at-home injections approximately every eight weeks.

Affecting nearly half a million people in the United States, Crohn's disease presents a significant treatment challenge. This raises a critical question for many patients and clinicians: Is upadacitinib effective in the real-world for Crohn's disease?

According to drug interaction databases, combining mesalamine with other medications that can affect the kidneys, such as meloxicam, may increase the risk of kidney damage. Due to this significant risk, anyone asking, 'Can you take meloxicam with mesalamine?', must consult a healthcare professional before combining these two drugs.

While mesalamine is a primary treatment for reducing inflammation in inflammatory bowel disease (IBD), leading to a reduction in diarrheal symptoms, studies show it can paradoxically cause diarrhea as a potential side effect. Understanding whether this is a minor issue or a sign of drug intolerance is crucial for proper management.

An estimated 20% of the US population has a genetic mutation affecting folate metabolism, highlighting the importance of understanding this vital nutrient. Folic acid plays a multifaceted and crucial role in the gut, extending beyond basic nutrient absorption to influence the delicate balance of the gut microbiome, intestinal cell health, and inflammation.

Prednisone, a powerful corticosteroid, can cause a range of gastrointestinal side effects, and research shows that high doses can significantly increase the risk of intestinal permeability, often referred to as 'leaky gut'. Understanding this connection is crucial for patients managing inflammatory conditions.

Toxic megacolon is a rare but severe complication of inflammatory bowel disease (IBD) or infectious colitis, characterized by extreme dilation of the colon [1]. While the underlying condition is the primary driver, certain medications can precipitate or worsen this life-threatening situation [1]. Understanding what drugs cause toxic megacolons is crucial for patients and healthcare providers to mitigate risk [2].

Studies show that Hyrimoz is highly similar to Humira, offering comparable safety, effectiveness, and quality for treating various inflammatory diseases. The key difference lies in Hyrimoz's status as a biosimilar, which allows for a more affordable alternative to the original Humira.

Over 20% of patients with moderate to severe plaque psoriasis receiving bimekizumab in clinical trials experienced an upper respiratory tract infection, highlighting the drug's effect on the immune system. This emphasizes why understanding the contraindications for bimekizumab is crucial for patient safety, as certain pre-existing conditions can increase the risk of serious side effects.

For patients with autoimmune diseases, biologics can be life-changing, yet an estimated 30-40% of patients on biologics for conditions like rheumatoid arthritis stop treatment due to non-response or loss of efficacy. This can be a frustrating and confusing experience, leaving many to wonder, **why do biologics stop working?**